13 results
8-K
EX-1.1
BGLC
BioNexus Gene Lab Corp
24 Jul 23
BioNexus Gene Lab Corp. Announces Pricing of $5 Million Public Offering and Uplisting to the Nasdaq Capital Market
5:28pm
”), the United Nations Security Council, the European Union, Her Majesty’s Treasury, or other relevant sanctions authority (collectively, “Sanctions”), nor
424B4
BGLC
BioNexus Gene Lab Corp
21 Jul 23
Prospectus supplement with pricing info
3:37pm
in the United States or the European Union. If BGL were to conduct extensive clinical trials, the results might prove to be less successful than we anticipate
10-K
xfzddcat99c2e2h2dzn
31 Mar 20
Annual report
1:12pm
S-1/A
u4gyic yjgdtq6yxch
25 Feb 19
IPO registration (amended)
3:30pm
S-1
r40ikrnf3cq391h 2u
29 Jan 19
IPO registration
12:00am
- Prev
- 1
- Next